ABSCIENCES (EPA:AB) AB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosis
Transparency directive : regulatory news
29/12/2022 18:08
ABSCIENCES's latest news
15/05/2024 20:16
13/03/2024 12:58
07/03/2024 15:20
06/03/2024 20:21
29/02/2024 11:49
26/02/2024 18:32
28/11/2023 19:22
27/11/2023 08:04
29/09/2023 19:49
18/09/2023 18:05
Other stories
16/05/2024 05:28
16/05/2024 01:01
16/05/2024 06:49
15/05/2024 21:57
16/05/2024 02:27
15/05/2024 22:00
16/05/2024 03:31
16/05/2024 00:24
16/05/2024 06:46
15/05/2024 22:00
15/05/2024 17:16
15/05/2024 20:43
16/05/2024 01:00
15/05/2024 23:13
Biden trolls Trump as he challenges him to debate: 'I hear you're free Wednesdays' - The Independent
15/05/2024 19:50
16/05/2024 01:16
16/05/2024 03:22
15/05/2024 18:17
15/05/2024 20:45
15/05/2024 16:08
15/05/2024 19:00
15/05/2024 18:43
16/05/2024 02:28
16/05/2024 03:00
15/05/2024 22:30
15/05/2024 17:51
16/05/2024 00:52
16/05/2024 04:50
15/05/2024 22:24
15/05/2024 23:29
15/05/2024 11:44
15/05/2024 11:19
15/05/2024 17:00
14/05/2024 23:50
16/05/2024 07:00
15/05/2024 01:48
15/05/2024 17:08
15/05/2024 06:02